The U.S. Food and Drug Administration (FDA) greenlit Janssen’s long-acting, twice-per-year schizophrenia drug Invega Hafyera (paliperidone palmitate six-month). This is the first long-acting antipsychotic drug of its kind that provides six months’ control of symptoms with a single dose and is expected to benefit patients who have had difficulties adhering to a more strict treatment regimen.
Approval was based on data from a Phase III non-inferiority study that showed Invega Hafyera compared to Invega Trinza, a three-month formulation of paliperidone palmitate. The results from the Route 6 Study showed that 92.5% of patients treated with Invega Hafyera and 95% treated with Invega Trinza were relapse-free after one year of treatment. A definition of relapse included psychiatric hospitalization, self-injury, violent behavior, or suicidal/homicidal ideation. Research has consistently found a link between low adherence to schizophrenia treatment and relapse.
“For too long, we’ve accepted relapse as a normal part of living with schizophrenia, while research continues to demonstrate that stronger medication adherence means better patient outcomes,” Dr. Gustavo Alva, medical director at ATP Clinical Research and six-month paliperidone palmitate clinical trial investigator, said in a statement. “The Phase III trial results provide compelling evidence that six-month paliperidone palmitate offers longer-term symptom control with the fewest doses per year, which may support greater patient adherence.”
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.
Stock image by @CLIPAREA from Depositphotos